Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 29. During the call, company executives will provide an overview of Merck’s performance for the quarter.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend ENFLONSIA™ (clesrovimab-cfor) as an option for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants younger than 8 months of age who are born during or entering their first RSV season. The ACIP also voted to include ENFLONSIA in the Vaccines for Children Program—an important step in ensuring broad access to this preventive option for infants.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that scientific and commercial team leaders will host a virtual investor event where they will give an overview of the company’s advancing HIV treatment and prevention research pipeline on July 17, 2025, at 9:00 a.m. ET.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. HYPERION met its primary endpoint of time to clinical worsening (TTCW) as measured by a composite endpoint of all-cause death, the need for non-planned PAH-related hospitalization > 24 hours, atrial septostomy, lung transplantation, or PAH deterioration.
The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs.
Shareholders of Merck would probably like to forget the past six months even happened. The stock dropped 20.3% and now trades at $79.30. This might have investors contemplating their next move.
MERCK & CO. (NYSE:MRK) is a top dividend stock with a 3.96% yield, strong profitability, and solid financial health, making it a compelling choice for income investors.
The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) with disease progression during or after treatment with an androgen receptor pathway inhibitor.
